NASDAQ:NRIX

Nurix Therapeutics Competitors

$29.99
+3.43 (+12.91 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.53
Now: $29.99
$32.29
50-Day Range
$26.56
MA: $34.44
$45.96
52-Week Range
$15.21
Now: $29.99
$52.38
Volume812,158 shs
Average Volume497,319 shs
Market Capitalization$1.33 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Nurix Therapeutics (NASDAQ:NRIX) Vs. SANA, ABCM, SEER, NUVB, IBRX, and IMCR

Should you be buying NRIX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Nurix Therapeutics, including Sana Biotechnology (SANA), Abcam (ABCM), Seer (SEER), Nuvation Bio (NUVB), ImmunityBio (IBRX), and Immunocore (IMCR).

Sana Biotechnology (NASDAQ:SANA) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Insider & Institutional Ownership

82.0% of Nurix Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Sana Biotechnology and Nurix Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sana BiotechnologyN/AN/AN/A
Nurix TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Sana Biotechnology and Nurix Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sana BiotechnologyN/AN/AN/AN/AN/A
Nurix TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for Sana Biotechnology and Nurix Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sana Biotechnology02202.50
Nurix Therapeutics00603.00

Sana Biotechnology currently has a consensus target price of $40.00, suggesting a potential upside of 59.74%. Nurix Therapeutics has a consensus target price of $46.80, suggesting a potential upside of 56.05%. Given Sana Biotechnology's higher possible upside, research analysts clearly believe Sana Biotechnology is more favorable than Nurix Therapeutics.

Summary

Nurix Therapeutics beats Sana Biotechnology on 3 of the 4 factors compared between the two stocks.

Abcam (NASDAQ:ABCM) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Insider & Institutional Ownership

82.0% of Nurix Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Abcam and Nurix Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbcamN/AN/AN/A
Nurix TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Abcam and Nurix Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbcamN/AN/AN/AN/AN/A
Nurix TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for Abcam and Nurix Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abcam04302.43
Nurix Therapeutics00603.00

Abcam currently has a consensus target price of $22.00, suggesting a potential upside of 12.47%. Nurix Therapeutics has a consensus target price of $46.80, suggesting a potential upside of 56.05%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Abcam.

Summary

Nurix Therapeutics beats Abcam on 4 of the 4 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Profitability

This table compares Seer and Nurix Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
Nurix TherapeuticsN/AN/AN/A

Insider & Institutional Ownership

82.0% of Nurix Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Seer and Nurix Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
Nurix TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for Seer and Nurix Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
Nurix Therapeutics00603.00

Seer currently has a consensus target price of $68.00, suggesting a potential upside of 26.25%. Nurix Therapeutics has a consensus target price of $46.80, suggesting a potential upside of 56.05%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Seer.

Summary

Nurix Therapeutics beats Seer on 4 of the 4 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Profitability

This table compares Nuvation Bio and Nurix Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvation BioN/AN/AN/A
Nurix TherapeuticsN/AN/AN/A

Insider and Institutional Ownership

82.0% of Nurix Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Nuvation Bio and Nurix Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation BioN/AN/AN/AN/AN/A
Nurix TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for Nuvation Bio and Nurix Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvation Bio00603.00
Nurix Therapeutics00603.00

Nuvation Bio presently has a consensus target price of $17.40, suggesting a potential upside of 74.52%. Nurix Therapeutics has a consensus target price of $46.80, suggesting a potential upside of 56.05%. Given Nuvation Bio's higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Nurix Therapeutics.

ImmunityBio (NASDAQ:IBRX) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a summary of current ratings for ImmunityBio and Nurix Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunityBio00103.00
Nurix Therapeutics00603.00

ImmunityBio presently has a consensus target price of $25.00, suggesting a potential upside of 38.35%. Nurix Therapeutics has a consensus target price of $46.80, suggesting a potential upside of 56.05%. Given Nurix Therapeutics' higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than ImmunityBio.

Profitability

This table compares ImmunityBio and Nurix Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunityBioN/AN/AN/A
Nurix TherapeuticsN/AN/AN/A

Valuation and Earnings

This table compares ImmunityBio and Nurix Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBioN/AN/AN/AN/AN/A
Nurix TherapeuticsN/AN/AN/AN/AN/A

Insider and Institutional Ownership

82.0% of Nurix Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Nurix Therapeutics beats ImmunityBio on 3 of the 3 factors compared between the two stocks.

Nurix Therapeutics (NASDAQ:NRIX) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Insider & Institutional Ownership

82.0% of Nurix Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Nurix Therapeutics and Immunocore, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nurix Therapeutics00603.00
Immunocore01202.67

Nurix Therapeutics presently has a consensus target price of $46.80, indicating a potential upside of 56.05%. Immunocore has a consensus target price of $54.3333, indicating a potential upside of 37.55%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Nurix Therapeutics is more favorable than Immunocore.

Earnings & Valuation

This table compares Nurix Therapeutics and Immunocore's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nurix TherapeuticsN/AN/AN/AN/AN/A
ImmunocoreN/AN/AN/AN/AN/A

Profitability

This table compares Nurix Therapeutics and Immunocore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nurix TherapeuticsN/AN/AN/A
ImmunocoreN/AN/AN/A

Summary

Nurix Therapeutics beats Immunocore on 4 of the 4 factors compared between the two stocks.


Nurix Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sana Biotechnology logo
SANA
Sana Biotechnology
1.2$25.04+3.4%$4.70 billionN/A0.00News Coverage
Abcam logo
ABCM
Abcam
1.5$19.56+0.6%$4.43 billionN/A0.00Lockup Expiration
SEER
Seer
1.2$53.86+5.7%$3.28 billionN/A0.00Increase in Short Interest
Nuvation Bio logo
NUVB
Nuvation Bio
2.2$9.97+0.4%$2.17 billionN/A0.00Analyst Report
Insider Buying
IBRX
ImmunityBio
1.7$18.07+7.2%$1.98 billionN/A0.00Gap Down
Immunocore logo
IMCR
Immunocore
1.3$39.50+16.5%$1.70 billionN/A0.00
BioAtla logo
BCAB
BioAtla
1.7$46.04+0.1%$1.55 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$35.47+9.0%$1.54 billionN/A0.00
EWTX
Cricut
0.3$28.15+1.0%$1.34 billionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$38.29+11.0%$1.34 billionN/A0.00Analyst Report
KNTE
Kinnate Biopharma
1.7$30.72+7.6%$1.34 billionN/A0.00Increase in Short Interest
Vor Biopharma logo
VOR
Vor Biopharma
1.9$33.72+13.6%$1.25 billionN/A0.00
FDMT
4D Molecular Therapeutics
1.1$37.68+5.1%$1.01 billionN/A0.00Increase in Short Interest
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
1.7$17.45+2.9%$974.01 millionN/A0.00Analyst Report
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$29.59+2.5%$942.15 millionN/A0.00Gap Down
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.96+8.3%$870.42 millionN/A0.00Analyst Report
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$12.94+7.1%$848.39 millionN/A0.00
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$23.99+4.0%$842.03 millionN/A0.00Analyst Report
Increase in Short Interest
PHAR
Pharming Group
0.0$13.00+1.9%$829.48 millionN/A0.00Decrease in Short Interest
News Coverage
FNCH
Finch Therapeutics Group
2.0$16.66+2.0%$785.44 millionN/A0.00Analyst Report
News Coverage
SGTX
Sigilon Therapeutics
1.4$19.88+6.2%$626.08 millionN/A0.00Increase in Short Interest
News Coverage
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$21.65+17.8%$543.96 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$23.89+12.3%$543.69 millionN/A0.00Gap Down
Inventiva logo
IVA
Inventiva
1.4$13.60+2.9%$525.37 millionN/A0.00Gap Up
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$11.54+2.0%$496.21 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Landos Biopharma logo
LABP
Landos Biopharma
1.8$11.26+5.8%$451.73 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.75+2.8%$451.17 millionN/A0.00
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$15.13+5.6%$446.09 millionN/A0.00Gap Up
PRTG
Portage Biotech
0.0$28.17+3.8%$340.38 millionN/A0.00Gap Down
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.61+2.5%$306.86 millionN/A-2.98
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.87+3.6%$291.75 millionN/A-2.72
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.83+3.9%$269.69 millionN/A0.00
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$10.94+7.3%$209.16 millionN/A0.00Increase in Short Interest
LBPH
Longboard Pharmaceuticals
1.9$12.15+2.4%$205.54 millionN/A0.00Analyst Report
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$22.90+5.4%$159.09 millionN/A0.00
GANX
Gain Therapeutics
1.7$14.02+5.8%$158.90 millionN/A0.00Analyst Report
VINC
Vincerx Pharma
1.0$19.05+0.6%$156.31 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$7.33+11.2%$140.73 millionN/A0.00News Coverage
LGVN
Longeveron
0.3$7.49+2.3%$140.12 millionN/A0.00
UPC
Universe Pharmaceuticals
0.0$3.92+4.3%$85.26 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$14.46+6.3%$56.51 millionN/A0.00Decrease in Short Interest
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.31+2.3%$53.37 millionN/A0.00Gap Down
VIRI
Virios Therapeutics
1.3$5.90+0.8%$49.15 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.29+2.1%$38.75 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$4.87+5.1%$33.17 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3N/AN/A$23.39 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$35.01+12.4%$16.25 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.84+4.9%$15.69 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$3.20+12.8%$2.47 millionN/A0.00Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.73+5.5%$0.00N/A0.00
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.